Mid*Lands IRB
, LLC is pleased to announce that it has been awarded accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) at the September meeting of its Council on Accreditation.
Located in the Kansas City metro area, Mid*Lands is an independent review board (IRB) that protects the rights and welfare of research study participants. Mid*Lands IRB specializes in providing customized, personalized, and responsive services for its client partners. Mid*Lands provides IRB review for clients nationwide for all phases of research in all therapeutic areas. Mid*Lands has extensive experience in multi-site trials, with two Boards that meet weekly.
AAHRPP promotes high-quality research through an accreditation process that helps organizations worldwide strengthen their human research protection programs (HRPPs).
An independent, non-profit accrediting body, AAHRPP uses a voluntary, peer-driven, educational model to ensure that HRPPs meet rigorous standards for quality and protection. To earn accreditation, organizations must provide tangible evidence through policies, procedures, and practices of their commitment to scientifically and ethically sound research and continuous improvement.
As the "gold seal," AAHRPP accreditation offers assurances to research participants, researchers, sponsors, government regulators, and the general public that an HRPP is focused first and foremost on excellence.
"After a tremendous amount of work by both our staff and our IRB Members, Mid*Lands has achieved full accreditation," according to Cathy Owen, CIM, CIP, CCRP, President and CEO of Mid*lands. "The rigorous and comprehensive accreditation mandated by AAHRPP provides Mid*Lands with the ability to achieve even higher levels of protection for human research participants," Ms. Owen said.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.